Navigation Links
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
Date:11/4/2014

SAN DIEGO, Nov. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer.

"We are very pleased to welcome Darin Lippoldt to the Neurocrine leadership team as our Chief Legal Officer," said Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences. "Darin's breadth of experience in both developmental and commercial biotechnology companies will be of critical importance as Neurocrine evolves into a fully-integrated pharmaceutical company."

Prior to joining Neurocrine, Mr. Lippoldt served as Executive Vice President and General Counsel of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations, and a J.D. from St Mary's University.

Neurocrine also announced the grant of an inducement award to Mr. Lippoldt pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules in connection with his employment with Neurocrine. In connection with the employment agreement, Mr. Lippoldt was granted an inducement award consisting of a stock option to purchase 95,000 shares of Neurocrine common stock. The stock option will vest over a period of four years, with 25% vesting on the first anniversary of the grant date and the balance vesting each month over the remaining three years. This award is subject to the terms and conditions of Neurocrine's Inducement Plan. This award was effective on November 3, 2014, the first business day of the first calendar month following the commencement of his employment with Neurocrine, and has an exercise price of $18.15 per share, which was the closing price of Neurocrine's common stock on the NASDAQ Global Select Market on that date. The award was granted as an inducement material to Mr. Lippoldt's employment pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
2. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
3. Neurocrine Biosciences Reports Third Quarter 2013 Results
4. Neurocrine Biosciences Reports Second Quarter 2013 Results
5. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
6. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
7. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
8. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
9. Neurocrine Biosciences Reports Third Quarter 2012 Results
10. Neurocrine Biosciences Reports Second Quarter 2012 Results
11. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... two-dimensional representations of a complex biological network, a depiction of a system of ... mess,” said Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... United States multicenter, prospective clinical study that demonstrates the accuracy of the ... of identifying clinically significant acute bacterial and viral respiratory tract infections by ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
Breaking Biology News(10 mins):